Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Income (2022 - 2025)

Taysha Gene Therapies' Operating Income history spans 4 years, with the latest figure at -$34.0 million for Q3 2025.

  • For Q3 2025, Operating Income fell 31.38% year-over-year to -$34.0 million; the TTM value through Sep 2025 reached -$102.1 million, down 16.36%, while the annual FY2024 figure was -$91.5 million, 26.26% down from the prior year.
  • Operating Income for Q3 2025 was -$34.0 million at Taysha Gene Therapies, down from -$26.8 million in the prior quarter.
  • Across five years, Operating Income topped out at -$16.2 million in Q4 2023 and bottomed at -$54.0 million in Q4 2022.
  • The 4-year median for Operating Income is -$24.3 million (2024), against an average of -$27.2 million.
  • The largest annual shift saw Operating Income skyrocketed 69.9% in 2023 before it tumbled 59.37% in 2024.
  • A 4-year view of Operating Income shows it stood at -$54.0 million in 2022, then skyrocketed by 69.9% to -$16.2 million in 2023, then dropped by 22.69% to -$19.9 million in 2024, then tumbled by 70.7% to -$34.0 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Operating Income are -$34.0 million (Q3 2025), -$26.8 million (Q2 2025), and -$21.4 million (Q1 2025).